National Health Act 1953 - Declaration under subsection 85(2AA) (No. PB 10 of 1997)

Overview

The National Health Act 1953 was enacted to establish a framework for national health services, including the Pharmaceutical Benefits Scheme (PBS) that subsidises the cost of certain medications for Australian residents. The legislation was introduced to address the need for a systematic and equitable approach to providing access to essential medications. The Act was enacted by the Parliament of Australia to provide policy objectives including the promotion of public health and ensuring affordable access to medicines. The legislative instrument F2007B01085, issued under the authority of the Act, includes a declaration made by the Acting Assistant Secretary of the Pharmaceutical Benefits Branch, acting on behalf of the Minister for Health and Family Services, to cease the listing of certain drugs and medicinal preparations on the PBS. This particular declaration, effective from 1 August 1997, removes Cloxacillin Sodium, Fluoxymesterone, and Ticarcillin Sodium from the list of subsidised medications, reflecting changes in medical practice, availability of alternative treatments, or other policy considerations aimed at managing the scheme’s resources effectively.

Scope and Application

The National Health Act 1953 governs various aspects of health services and pharmaceutical benefits within Australia. Under this Act, specific drugs and medicinal preparations are subject to the regulatory framework outlined in Part VII. The Pharmaceutical Benefits Declaration under Subsection 85 (2AA) of the Act, made by the Acting Assistant Secretary of the Pharmaceutical Benefits Branch, designates certain drugs and medicinal preparations that will no longer be covered under the Pharmaceutical Benefits Scheme. This particular legislative instrument, numbered PB 10 of 1997, applies to Cloxacillin Sodium, Fluoxymesterone, and Ticarcillin Sodium, removing them from the list of drugs eligible for subsidies under the National Health Act. The scope of this Act is broad, applying to all individuals and entities within Australia that are involved in the distribution or prescription of pharmaceutical products. The geographic reach of this legislation is national, extending across the Commonwealth of Australia. The Act does not specify any exclusions, exemptions, or thresholds for its application. Its application may also be extended or restricted through subordinate instruments, which provide further detail on the administration and implementation of the Act's provisions.

Key Provisions

The main operative sections of this legislative instrument pertain to the cessation of certain drugs and medicinal preparations from being covered under Part VII of the National Health Act 1953. Specifically, the Declaration under subsection 85 (2AA) (section 2) identifies that Cloxacillin Sodium, Fluoxymesterone, and Ticarcillin Sodium will no longer be subject to the provisions of the Act from 1 August 1997. This legislative change is effective from the date specified in the Declaration, and it directly impacts the status of these drugs and preparations by removing them from the list of those covered by the Pharmaceutical Benefits Scheme. The Act imposes specific obligations on entities and parties that deal with these pharmaceuticals. Manufacturers, suppliers, and healthcare providers must adjust their practices to account for the fact that these medications are no longer part of the covered list. This may involve changes in how these drugs are prescribed, dispensed, and reimbursed, as they will no longer be eligible for the benefits provided under the Pharmaceutical Benefits Scheme. Consequently, healthcare professionals and patients must be aware of these changes to avoid any disruptions in treatment and to understand the financial implications associated with the medications. Breach of the provisions set out in this legislative instrument could lead to various civil and criminal consequences. For instance, if a pharmaceutical product listed in the Schedule is still claimed for benefits under Part VII of the Act after the effective date, it could be considered a breach. While the Act does not specify maximum penalties for such breaches, penalties for similar violations in the broader context of the National Health Act 1953 can include fines and other legal actions. It is crucial for all stakeholders to adhere to the declared changes to avoid potential legal ramifications.